HIMS · Hims & Hers Health, Inc.

Track HIMS — free

$32.70 -0.14 (-0.43%) At close · Jul 20

Market Cap

$7.57B

231.46M

Up next

Next earnings call

Aug 10, 2026 Scheduled · in 3 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 11, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Neutral Sentiment Bullish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 18.7 · elevated Equity put/call 0.66

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +4%

above

Price vs 50-day avg +9%

above

RSI (14) 48

neutral

MACD trend Negative

52-week position 33%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return −8%

trailing

6-month return +8%

trailing

YTD return +1%

this year

Relative strength +1%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $30 › 200d $32 — 200d above 50d

Institutional flow Accumulating

45 of 442 funds reported for Jun 30 · net +633.3K sh shares · +14 new

Insider flow Accumulating

Net +$985.1K over 90 days · 50% sells

Short interest Falling

26.43% of float · ▼ -6.6% MoM · 3.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

442 holders — mid 3-yr range

Squeeze score 76

high risk · 0–100

Fundamentals

Excellent

Revenue growth +59%

Y/Y

Gross margin 74%

contracting

EPS growth −4%

Y/Y

Buyback $225.0M

remaining

Balance sheet $228.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 91%

annualized · 1-yr

Max drawdown −78%

past year

ATR 7.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Equibles Research

All HIMS research

Research Thesis July 19, 2026

Hims & Hers has 26.4% shorts arguing against $2.9B of guided 2026 revenue; the Q2 print decides whether subscriber growth or ARPU decay wins

Hims & Hers closed at $32.84, off 50.4% from its 52-week high, with short interest at 26.4% of shares outstanding and the steepest positioning in the comp set against a +59.0% TTM revenue base and a 10%–12% full-year adjusted EBITDA guide — the next quarter decides whether the multiple re-rates with subscriber growth or compresses further on the 6% ARPU slide.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed May 11, 2026

second quarter 2026

Revenue Initiated $680M – $700M

prior qtr $608.1M midpoint +13.5% QoQ

Adjusted EBITDA Non-GAAP Initiated $35M – $55M

Adjusted EBITDA margin Non-GAAP Initiated 5% – 8%

full year 2026

Revenue Initiated $2.8B – $3B

prior FY $2.35B midpoint +23.5% Y/Y

Adjusted EBITDA Non-GAAP Initiated $275M – $350M

Adjusted EBITDA margin Non-GAAP Initiated 10% – 12%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+4% Bullish

Price vs 50-day avg

+9% Bullish

RSI (14)

48 Neutral

MACD trend

Negative Bearish

52-week position

33% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $30 › 200d $32 — 200d above 50d

Institutional flow Accumulating

45 of 442 funds reported for Jun 30 · net +633.3K sh shares · +14 new

Insider flow Accumulating

Net +$985.1K over 90 days · 50% sells

Short interest Falling

26.43% of float · ▼ -6.6% MoM · 3.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

442 holders — mid 3-yr range

Price context

position in its 52-week range

52-wk low $14 Now $33 · 33% 52-wk high $70

vs 200-day avg +4% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	$44.3M	the first quarter of 2026	—

Free Cash Flow non-GAAP	$57.4M	the year ended December 31	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
HIMS Hims & Hers Health, Inc. this stock	$7.57B	+0.7%	+59.0%	—	26.4%
TAK Takeda Pharmaceutical Co Ltd	$54.45B	+9.4%	—	—	0.2%
GALDY Galderma Group AG/ADR	$50.12B	+3.1%	—	—	0.0%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$45.13B	—	—	—	0.0%
HLN Haleon plc	$44.21B	-0.7%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

448

% held: 88.2%
Reported: 45 of 442
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

320

View

Short & Settlement

Short Interest Falling

Shares short

61.2M

Days to cover: 3.2d
Change: -4.3M sh

View

Short Volume

Short vol %

67%

As of: Jul 20, 2026

Short Total

View

Fails to Deliver

FTD shares

53.8K

Value: $1.8M
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

54.2%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$985.1K

Buyers / Sellers: 1 / 1

Buyers Sellers

View

Congressional Trades Buy

Member

Lisa McClain

Amount: $1.0K–$15.0K
Traded: Aug 4, 2025

View

Financials

Revenue (FY)

$2.3B

Net income (FY): $128.4M
EPS diluted: $0.51

View

Buybacks

Authorized

$250.0M

Remaining: $225.0M

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 17, 2026
This year: 13

View

Proposed Sales

Value

$830.4K

Shares: 23.7K
Filed: Jun 18, 2026

View

Earnings & Events

Earnings Calls Upcoming

Next call

Aug 10, 2026

Last call: May 11, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
HIMS	-4.9%	-7.8%	+8.0%	-5.7%	+0.7%
SPY	-1.0%	-0.6%	+7.1%	-0.6%	+8.8%
vs SPY	-3.9%	-7.2%	+0.9%	-5.1%	-8.1%

Capital returns

Buyback program · as of Mar 31, 2026

Authorized

$250.00M

Spent (derived)

$25.00M

Remaining

$225.00M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1773751 CUSIP 433000106 13F (30d) 41 filings 40 filers Visit website Investor relations

HIMS · Hims & Hers Health, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Equibles Research

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns